|Articles|March 17, 2021
Seasonal Vaccine Manufacturing
Author(s)Baxter BioPharma Solutions
The seasonal influenza vaccine market is projected to reach more than $4 Billion USD by the end of 2022. It is a safe assumption that as demand for seasonal influenza vaccines increases, so too with the demand for contract manufacturing organizations (CMOs) to support.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
CPHI Frankfurt 2025 Highlights Global Pharma Innovation and Manufacturing Leadership
2
Applying Analytical Quality by Design Principles to Biopharma Method Development and Optimization
3
AstraZeneca Lupus Treatment Support in EU Opens Door for Self-Administration Options
4
Why Radiopharmaceuticals Are Ideal for Treating Cancer
5
